Comparison of GR32191, R68070 and CV-4151 upon U-46619- and collagen-induced platelet aggregation in vitro and ex vivo.
Watts
I S
IS
Department of Cardiovascular Pharmacology, Glaxo Group Research Ltd, Ware, Herts.
White
B P
BP
Wharton
K A
KA
Lumley
P
P
D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D001713:Biphenyl Compounds / Q000494:pharmacology*; D003094:Collagen / Q000494:pharmacology; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology*; D006538:Heptanoic Acids / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D010421:Pentanoic Acids / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*; D011450:Prostaglandin Endoperoxides, Synthetic / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology*; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*; D014631:Valerates / Q000494:pharmacology*
D001713:Biphenyl Compounds; D005229:Fatty Acids, Monounsaturated; D006538:Heptanoic Acids; D010421:Pentanoic Acids; D011450:Prostaglandin Endoperoxides, Synthetic; D011725:Pyridines; D014631:Valerates; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D003094:Collagen; D013930:Thromboxane-A Synthase; C060013:vapiprost; C045446:isbogrel; C060219:ridogrel